Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.266183 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Liang Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, …. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Extensive research has been conducted on radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2 (LM3) peptides for imaging of FAP and somatostatin receptor 2 (SSTR2)-positive tumors. In this study, we designed and synthesized a FAPI-LM3 heterobivalent molecule radiolabeled with 68Ga and evaluated its effectiveness in both tumor xenografts and patients with nasopharyngeal carcinoma (NPC).
Methods
The synthesis of FAPI-LM3 was based on the structures of FAPI-46 and LM3. After radiolabeling with 68Ga, its dual-receptor-binding affinity was evaluated in vitro and in vivo. Preclinical studies, including small-animal PET and biodistribution evaluation, were conducted on HT-1080-FAP and HT-1080-SSTR2 tumor xenografts. The feasibility of 68Ga-FAPI-LM3 PET/CT in a clinical setting was evaluated in patients with NPC, and the results were compared with those of 18F-FDG.
Results
68Ga-FAPI-LM3 showed high affinity for both FAP and SSTR2. The tumor uptake of 68Ga-FAPI-LM3 was significantly higher than that of 68Ga-FAPI-46 and 68Ga-DOTA-LM3 in HT-1080-FAP-plus-HT-1080-SSTR2 tumor xenografts. In a clinical study involving 6 NPC patients, 68Ga-FAPI-LM3 PET/CT showed significantly higher uptake than did 18F-FDG in primary and metastatic lesions, leading to enhanced lesion detectability and tumor delineation.
Conclusion
68Ga-FAPI-LM3 exhibited FAPI and SSTR2 dual-receptor-targeting properties both in vitro and in vivo, resulting in improved tumor uptake and retention compared with that observed with monomeric 68Ga-FAPI and 68Ga-DOTA-LM3. This study highlights the clinical feasibility of 68Ga-FAPI-LM3 PET/CT for NPC imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
- Xiamen Key Laboratory of Radiation Oncology, Department of Radiation Oncology, Xiamen Cancer Center, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
- State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics and Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, China; and.
- School of Clinical Medicine, Fujian Medical University, Fuzhou, China; leochen0821@foxmail.com linqin05@163.com.
- Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China; leochen0821@foxm…
Zitieren
APA
Zhao, L., Pang, Y., Fang, J., Chen, J., Zhou, Y., Sun, L., Wu, H., Guo, Z., Lin, Q., & Chen, H. (2024). Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.266183
Vancouver
Zhao L, Pang Y, Fang J, Chen J, Zhou Y, Sun L, et al. Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.266183
BibTeX
@article{Zhao2024,
author = {Zhao, Liang and Pang, Yizhen and Fang, Jianyang and Chen, Jianhao and Zhou, Yangfan and Sun, Long and Wu, Hua and Guo, Zhide and Lin, Qin and Chen, Haojun},
title = {Design, Preclinical Evaluation, and Clinical Translation of 68 Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.266183}
}
EUVIMED